[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352191-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352191-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","epidemiology-de-novo-cancer-related-mortality-after-solid-organ-transplantation-in-england-the-epcot-study","Epidemiology - De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study","","Cancer remains a major cause of mortality after solid organ transplantation (SOT), yet estimating de novo cancer-related death risk is challenging because prior evidence is heterogeneous and methodologically limited. A population-based cohort study linked the UK Transplant Registry with national cancer, death registration, and hospital episode datasets for all SOT recipients in England from June 1992 to December 2015. Among 50,762 recipients, cancer caused 15.9% of deaths, ranked second overall, with risk varying by transplant and cancer subtype.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/epidemiology-de-novo-cancer-related-mortality-after-solid-organ-transplantation-in-england-the-epcot-study/352191/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/epidemiology-de-novo-cancer-related-mortality-after-solid-organ-transplantation-in-england-the-epcot-study/352191.png","ImageObject",300,407,{"name":42,"@type":43},"MrHarris58","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the EpCOT study address about SOT recipients in England?","Question",{"text":63,"@type":64},"It examines de novo cancer-related mortality after solid organ transplantation and characterizes how risk varies by cancer type and/or allograft.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was mortality and cancer data obtained for SOT recipients?",{"text":68,"@type":64},"The study used retrospective population-based record linkage, connecting the UK Transplant Registry with national cancer registration, death registration, and hospital episode statistics.",{"name":70,"@type":61,"acceptedAnswer":71},"Which transplant group showed the highest and lowest cancer mortality risk?",{"text":72,"@type":64},"Cancer mortality was highest among lung transplant recipients and lowest among kidney transplant recipients, based on standardized mortality ratios.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352191,1790169794,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www.nature.com/bjc](www.nature.com/bjc British)[ British](www.nature.com/bjc British) Journal of Cancer  \nARTICLE OPEN   \nEpidemiology  \nDe novo cancer-related mortality after solid organ transplantation in England: the EpCOT study  \nCharlotte Stephens 1,2, David Winter3, Mike Hawkins3, Raoul Reulen 3 and Adnan Sharif1,2 ✉  \n© The Author(s) 2026  \n\n|  | BACKGROUND: Cancer is a major cause of mortality after solid organ transplantation (SOT) . Quantifying this risk is difﬁcult due to heterogeneous reports and methodological limitations.\u003Cbr>METHODS: We conducted a population-based cohort study linking data between the UK Transplant Registry, National Cancer Registry, Civil Registration of Deaths, and Hospital Episode Statistics for all SOT recipients in England between 1st June 1992 and 31st December 2015 .\u003Cbr>FINDINGS: Among 50,762 SOT recipients, 22,361 deaths were recorded, of which 3550 (15.9%) were due to cancer, making it the second leading cause of mortality. Overall cancer (excluding non-melanomatous skin cancer) standardised mortality ratio (SMR) was 2.12 (95% CI: 2.05–2.19) . Cancer mortality was highest among lung recipients (SMR 3.49; 95% CI: 2.96–4.06), and lowest in kidney recipients (SMR 2.00; 95% CI: 1.92–2.08) . Non-Hodgkin’s Lymphoma had highest mortality after SOT (SMR 9.86; 95% CI: 9.01–10.75) and was elevated across all transplant types. However, liver and kidney cancer mortality was disproportionately elevated among liver (SMR: 9.30; 95% CI: 7.53–11.24) and kidney transplant recipients (SMR: 5.11; 95% CI: 4.34–5.93), respectively. Several cancers showed no increased mortality.\u003Cbr>INTERPRETATION: De novo cancer remains a major cause of long-term mortality after SOT in England, with risk stratiﬁed by cancer |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| and/or allograft. |  |  |\n|  | British Journal of Cancer (2026) 135:1086–1093; [https://doi.org/10.1038/s41416-026-03529-4](https://doi.org/10.1038/s41416-026-03529-4) |  |\n|  |  |  |\n\nINTRODUCTION  \nSolid organ transplantation (SOT) is a lifesaving or life-enhancing intervention for patients with end-stage organ failure [1]. Globally, 172,409 transplant procedures were documented as performed in 2023 [2], and over a million people currently live with an allograft. Balanced against transplantation survival beneﬁts, a lifelong requirement for anti-rejection therapy introduces susceptibility to immunosuppression-related complications such as cancer [3]. The underlying pathophysiology may relate to increased cumulative exposure to the direct oncogenic effects of certain immunosuppressive agents, an inﬂammatory milieu associated with organ failure, and increased susceptibility to oncogenic infections, frequently on a background of comorbidities associated with elevated cancer risk.  \nWhile cancer incidence is elevated for SOT recipients, that may not translate directly to elevated cancer-related mortality. SOT recipients have increased all-cause mortality versus the general population [4], with several competing risks for mortality including infection, cardiovascular disease or allograft failure. Previous work published over a decade ago demonstrated cancer-related mortality risk difference in England was higher after kidney transplantation versus the general population [5], However, this data relied upon hospital administration data alone which has  \nseveral methodological limitations [6] . It is imperative we improve our understanding of post-transplant cancer mortality risk to ensure appropriate counselling before transplantation and encourage evidence-based management post-transplantation. Globally, several studies have reported elevated cancer mortality risk versus the general population. However, the magnitude of risk isheterogenous and ranges from 1.4 in South Korea [7] up to 2.9 in Australia and New Zealand [8] . This variation highlights differ","cbCaig0L7iUWuMV6","https://ap.wps.com/l/cbCaig0L7iUWuMV6","pdf",418841,"English","# Background\n# Methods\n# Findings\n# Interpretation\n# Introduction\n# Methods: Data linkage","[{\"question\":\"What question does the EpCOT study address about SOT recipients in England?\",\"answer\":\"It examines de novo cancer-related mortality after solid organ transplantation and characterizes how risk varies by cancer type and/or allograft.\"},{\"question\":\"How was mortality and cancer data obtained for SOT recipients?\",\"answer\":\"The study used retrospective population-based record linkage, connecting the UK Transplant Registry with national cancer registration, death registration, and hospital episode statistics.\"},{\"question\":\"Which transplant group showed the highest and lowest cancer mortality risk?\",\"answer\":\"Cancer mortality was highest among lung transplant recipients and lowest among kidney transplant recipients, based on standardized mortality ratios.\"}]","Epidemiology - De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study | PDF",1790098250,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91e0065bfd7bc1457237187737178ef5.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f76ce75d49046f1e78012d63ba933173.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93364ca615afe099eb2eae05546a892a.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f28ff8006aa040778b1e5bbbaaa7f5ca.webp",980,1301]